AZ “Corona vaccine, 79% efficacy in large-scale US clinical trials…100% severe blockade” (2nd total)

In the US clinical trial, 32,449 people participated, of which about 20,000 were vaccinated and the rest were compared with placebo (placebo). About 20% of the participants in this clinical trial were aged 65 or older, and about 60% had so-called underlying diseases such as diabetes, obesity, and heart disease.

In a press release that day, AstraZeneca announced that its vaccine showed 79% efficacy in preventing the onset of COVID-19 symptoms, and particularly 100% effective in preventing progression to severe conditions requiring hospitalization.

In addition, AZ explained that the effect of 80% was slightly higher than the overall average in the elderly over 65 years old.

The vaccine has been shown to be effective in all age groups, including the elderly.

“These results reconfirm the results of previous clinical trials,” said Prof. Ahn Polsey, who led the phase 3 clinical study in the United States. “He said.

In particular, this US clinical trial showed that AZ’s corona vaccine did not increase the risk of clot formation.

AstraZeneca said it has confirmed that there are no safety concerns, such as rare cases of blood clots, such as those identified in Europe.

In this regard, the Associated Press reported that scholars did not find a case with an increased risk of blood clots among 20,000 clinical participants who received at least one AZ vaccine.

The European Medicines Agency (EMA) also decided to maintain the recommendation for approval as “safe and effective vaccine” as a result of a review on the case of thrombosis that occurred after vaccination with AZ in its announcement on the 18th.

The medical community has been waiting for the results of this clinical trial with anticipation that the new clinical trial will end the confusion over the effectiveness of the AstraZeneca vaccine, the Associated Press reported.

According to an AZ announcement at the end of last year, AstraZeneca’s Corona 19 vaccine showed an average immune effect during clinical trials of 70.4%, which was inferior to Pfizer (95%) and Modena (94.5%).